Trinity Life Sciences

Overview

Trinity Life Sciences is a Kohlberg & Company-backed life-sciences commercialization firm operating at the intersection of management consulting, proprietary benchmarking data (TGaS Advisors), and AI-powered SaaS analytics (TrinityEDGE). Founded in 1996, headquartered in Waltham, MA; Kohlberg acquired Trinity in November 2021, and Bain & Company took a minority strategic stake in August 2022 with C-suite engagement access.

Trinity is not a pure strategy boutique or a single-product analytics vendor. The buyer thesis is the combination: launch strategy plus proprietary benchmarking data plus AI-enabled forecasting plus Bain co-delivery access. Kohlberg’s pharma-services portfolio also includes PCI Pharma Services (CDMO) and Worldwide Clinical Trials (CRO); Trinity is the commercialization piece, not the CDMO or CRO.

Launch Capability Model

The framework below standardizes how Rx Almanac evaluates commercialization-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Trinity Life Sciences is evaluated as a life-sciences commercialization firm operating at the intersection of management consulting, TGaS benchmarking data, and TrinityEDGE analytics.

Capability	Buyer should compare	Trinity Life Sciences readout
Integrated launch strategy	Launch objectives, segmentation, positioning, sequencing, governance, and cross-functional launch plan.	Core. Launch Accelerator (TrinityEDGE module) plus TGaS launch benchmarking; involvement in ~70% of new drug launches.
Commercial model and operating design	Org model, channel model, field model, vendor model, process design, and operating cadence.	Core. TGaS membership benchmarks the majority of top 50 pharma operating models.
Market access and patient-services orchestration	Coverage strategy, hub design, reimbursement support, affordability, and patient-services vendor coordination.	Core. Combination of launch analytics, payer-segmentation work, and access-strategy advisory.
Analytics, forecasting, and opportunity sizing	Forecasts, market sizing, patient flow, targeting, launch KPIs, and scenario planning.	Core. ForecastEDGE for enterprise forecasting, InsightsEDGE for role-specific AI advisors; ~90% revenue-prediction accuracy on launches.
Change management and implementation support	PMO, stakeholder alignment, implementation roadmaps, SOPs, training, and execution governance.	Adjacent. TGaS benchmarks operating models, but implementation/PMO depth should be confirmed in RFP.
Portfolio and lifecycle strategy	Indication sequencing, lifecycle planning, portfolio tradeoffs, LOE, and expansion strategy.	Core. Corporate and commercial strategy includes portfolio planning, asset prioritization, and lifecycle work.

Buyer Fit

• Best shortlist motion: Manufacturers that want launch strategy, forecasting, benchmarking, and AI analytics under one firm rather than splitting across a strategy consultancy and an analytics vendor.
• Best-fit buyers: Mid-sized to large pharma; emerging biotechs preparing for a major launch and wanting TGaS benchmarks to calibrate operating model; teams that want Bain-grade C-suite access on specific engagements.
• Less ideal fit: Buyers seeking pure functional consulting (single-workstream HEOR, pure payer-strategy boutique) or those uninterested in the TrinityEDGE/TGaS data subscriptions.
• Commercial fit: Custom/RFP for consulting; TrinityEDGE and TGaS Advisors carry recurring subscription components (hybrid revenue model).
• Validate before award: Whether the engagement is consulting-led, TrinityEDGE-led, or TGaS-led; how Bain co-delivery is scoped when applicable; named senior operators.

Differentiators

• TGaS Advisors benchmarking membership: Majority of top 50 pharma participate; the benchmarking data is the operating-model backbone.
• TrinityEDGE AI platform: ForecastEDGE (enterprise forecasting), InsightsEDGE (role-specific AI advisors), Launch Accelerator. $100M+ invested in AI; Everest Group PEAK Matrix Leader in Life Sciences AI & Analytics.
• Bain & Company strategic alliance: Minority equity stake since Aug 2022; provides upmarket C-suite transformation access via Bain’s global reach.
• Launch density: Involvement in ~70% of new drug launches with reported ~90% revenue-prediction accuracy.
• Kohlberg pharma-services ecosystem: Non-competing platform with PCI Pharma Services (CDMO) and Worldwide Clinical Trials (CRO).

RFP Questions

• Which option is the engagement consulting-led, TrinityEDGE-led, or TGaS-led, and who is the named senior operator?
• Which TrinityEDGE modules (ForecastEDGE, InsightsEDGE, Launch Accelerator) are included, and on what licensing terms?
• What TGaS Advisors membership benefits and benchmarking outputs are in scope?
• What conditions make Bain & Company co-deliver, and what does that change in pricing, governance, and senior attribution?
• Which forecast-accuracy and launch-analog evidence can the team cite for our therapy area and asset class?
• How does Trinity coordinate with sibling Kohlberg portfolio companies (PCI, Worldwide Clinical Trials) when relevant?
• What change-order and pass-through-cost patterns apply across the bundled scope?

Recent Activity

• 2025-11 - Scott Evangelista appointed CEO, succeeding Leslie Orne (24+ years at Trinity).
• 2025-11 - Acquired EVERSANA’s Asia-Pacific and Middle East advisory services, adding offices in Singapore, Tokyo, Mumbai, Shanghai, Sydney, and Dubai.
• 2025-08 - Launched Trinity Digital Affinity (HCP digital engagement, powered by DeepIntent).
• 2025-07 - Opened Mexico City office; published AI model for early Type 1 diabetes detection at ADA 85th Scientific Sessions.
• 2022-08 - Bain & Company took minority strategic stake.
• 2021-11 - Kohlberg & Company acquired Trinity at ~$1.4B enterprise value (17-23x EBITDA).